Mereo Biopharma Group Plc - ADR
MREO
Get informed when a big investor buys or sells
+ FollowMarket Cap$48.36M
Close$
$0.26
24.9% downside
Current Fair Value
24.9% downsideOvervalued by 24.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $48.36 Million |
|---|---|
| Enterprise Value | $19.28 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.26 |
| Beta | 0.3 |
| Outstanding Shares | 160,712,541 |
Return
| Return on Equity | -98.03% |
|---|---|
| Return on Assets | -80.91% |
| Return on Invested Capital | -117.09% |
Valuation & Multiples
| P/E Ratio | -1.66 |
|---|---|
| PEG | 3.2 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.57 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 18, 2026
EPS Estimate
$-0.02
Average shareholder expectationRevenue Estimate
$2.33 M
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.01
Average shareholder expectationRevenue Estimate
$4.61 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1405▼ 19.33% |
|---|---|
| Total Calls | 690,200▲ 2.68% |
| Total Puts | 97,000▼ 56.77% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 35.23%▼ 11.78% |
|---|---|
| Total Invested | $17.98M▼ 27.70% |
| Investors Holding | 63▼ 4.00% |
ESG Score
No data
About Mereo Biopharma Group Plc
2,020 employees
CEO: Denise Pollard-Knight Mereo BioPharma is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. The Company has developed a portfolio of six clinical...